HomeCompareDVNHF vs PFE

DVNHF vs PFE: Dividend Comparison 2026

DVNHF yields 17421.60% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DVNHF wins by $13344525518322921472.00M in total portfolio value
10 years
DVNHF
DVNHF
● Live price
17421.60%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13344525518322921472.00M
Annual income
$13,195,528,879,709,603,000,000,000.00
Full DVNHF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — DVNHF vs PFE

📍 DVNHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDVNHFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DVNHF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DVNHF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DVNHF
Annual income on $10K today (after 15% tax)
$1,480,836.24/yr
After 10yr DRIP, annual income (after tax)
$11,216,199,547,753,161,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, DVNHF beats the other by $11,216,199,547,753,161,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DVNHF + PFE for your $10,000?

DVNHF: 50%PFE: 50%
100% PFE50/50100% DVNHF
Portfolio after 10yr
$6672262759161460736.00M
Annual income
$6,597,764,439,854,801,000,000,000.00/yr
Blended yield
98.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

DVNHF
No analyst data
Altman Z
1.8
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DVNHF buys
0
PFE buys
0
No recent congressional trades found for DVNHF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDVNHFPFE
Forward yield17421.60%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$13344525518322921472.00M$49.6K
Annual income after 10y$13,195,528,879,709,603,000,000,000.00$26,258.71
Total dividends collected$13334682069741707264.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DVNHF vs PFE ($10,000, DRIP)

YearDVNHF PortfolioDVNHF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$1,752,860$1,742,160.28$9,153$693.39+$1.74MDVNHF
2$287,274,023$285,398,462.79$8,593$849.25+$287.27MDVNHF
3$44,021,016,927$43,713,633,722.00$8,336$1,066.78+$44021.01MDVNHF
4$6,307,426,992,644$6,260,324,504,532.32$8,437$1,384.80+$6307426.98MDVNHF
5$845,060,071,102,951$838,311,124,220,822.10$9,013$1,875.40+$845060071.09MDVNHF
6$105,872,184,925,886,820$104,967,970,649,806,660.00$10,306$2,680.72+$105872184925.88MDVNHF
7$12,403,720,022,509,801,000$12,290,436,784,639,103,000.00$12,820$4,101.38+$12403720022509.79MDVNHF
8$1,358,988,608,024,558,200,000$1,345,716,627,600,472,500,000.00$17,673$6,826.70+$1358988608024558.25MDVNHF
9$139,249,194,965,718,820,000,000$137,795,077,155,132,540,000,000.00$27,543$12,591.86+$139249194965718816.00MDVNHF
10$13,344,525,518,322,921,000,000,000$13,195,528,879,709,603,000,000,000.00$49,560$26,258.71+$13344525518322921472.00MDVNHF

DVNHF vs PFE: Complete Analysis 2026

DVNHFStock

Frontier Services Group Limited, an investment holding company, provides aviation, logistics, security, insurance, and infrastructure related services. The company operates through Aviation and Logistics Business; Security, Insurance and Infrastructure Business; and Financial Market Information Business segments. It offers online financial market information. The company's security services include protective services and specialized training services; logistics services comprise engineering project logistics services and special logistics services, such as transportation of valuables; and infrastructure solutions include project planning, business consulting, investment and financing, engineering design, project implementation and operation, and support services. It also provides consultancy and freight forwarding services; finance, liability, property, and personnel insurance services; and healthcare and airport management services. The company serves the oil and gas, mining, finance, energy, and infrastructure industries, as well as organizations. It operates in Africa, Europe, the People's Republic of China, Mainland China, Hong Kong, southeast Asia, and the Middle East. The company was formerly known as DVN (Holdings) Limited and changed its name to Frontier Services Group Limited in March 2014. Frontier Services Group Limited is headquartered in Admiralty, Hong Kong.

Full DVNHF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this DVNHF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DVNHF vs SCHDDVNHF vs JEPIDVNHF vs ODVNHF vs KODVNHF vs MAINDVNHF vs JNJDVNHF vs MRKDVNHF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.